Chinook Therapeutics, Inc.
KDNYDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Atrasentan | Phase 3 | IgA Nephropathy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Chinook Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Chinook Therapeutics, Inc.'s (KDNY) pipeline across Phase 3. Its lead program is Atrasentan (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Chinook Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Chinook Therapeutics, Inc. (KDNY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KDNY biotech catalysts?→
Add KDNY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Chinook Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.